Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Biological warfare Stories

2013-07-31 12:26:46

PINE BROOK, N.J., July 31, 2013 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today released data from three recently completed studies of ETI-204 (Anthim) administered by intramuscular (IM) injection. ETI-204, an anthrax anti-toxin, is an investigational agent in late stage development for the treatment of inhalational anthrax infection. (Logo:...

Antibiotic Ocean Microbe Could Be An Anthrax Killer
2013-07-18 13:34:36

Lee Rannals for redOrbit.com - Your Universe Online Scientists writing in the journal Angewandte Chemie say they have discovered a new chemical compound from an ocean microbe that could open up new treatments for anthrax and other ailments. The team collected a microorganism that produced the compound close to shore off Santa Barbara, California. Initial testing of the compound, named anthracimycin, revealed its potency as a killer of anthrax, which is an infectious disease feared as a...

2013-07-03 16:22:51

ANNAPOLIS, Md., July 3, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that Eric I. Richman, President and Chief Executive Officer will present at the JMP Securities 2013 Healthcare Conference on Wednesday, July 10, 2013 at 3:30 p.m. E. T. in the Library Room, St. Regis Hotel, New York. Mr. Richman and Linda Chang, Senior Vice President and Chief Financial...

2013-07-01 12:27:28

Leadership Team Will Advance Industry Efforts Supporting the Development of Medical Countermeasures Against National Security Threats WASHINGTON, July 1, 2013 /PRNewswire/ -- The Alliance for Biosecurity announced it recently elected Anders Hedegaard, President and CEO, Bavarian Nordic, and Elizabeth Posillico, PhD, President and CEO, Elusys Therapeutics, as its new co-chairs. They will represent the Alliance before the U.S. government and other agencies, to advance the development...

2013-06-26 08:30:40

PRINCETON, N.J., June 26, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) ("Soligenix" or the "Company"), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that on June 25, 2013 it closed its previously announced registered public offering. The Company raised gross proceeds of approximately $7.1 million in the offering and intends to...

2013-06-21 08:24:43

PRINCETON, N.J., June 21, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) ("Soligenix" or the "Company"), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today the pricing of a registered public offering of shares of common stock and warrants to purchase common stock. In connection with the public offering, the Company has entered into...

2013-06-10 08:29:34

NEWARK, Del., June 10, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) today announced that its patent covering the composition and production of a human monoclonal antibody for the treatment of anthrax infection has been allowed in China. This patent, which will issue from Chinese patent application No.:200680036136.1, is entitled "COMPOSITIONS AND METHODS FOR PRODUCTION OF IMMUNOGLOBULINS." (Logo: http://photos.prnewswire.com/prnh/20120419/NY91086LOGO) The claims of the allowed patent...

2013-06-03 08:29:10

PLANTATION, Fla., June 3, 2013 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI) announced today the award of a sub-contract from Emergent BioSolutions for GBI to conduct some early stage proof-of-concept feasibility process development to investigate concentrating AVA filtrate for storage before the downstream process for BioThrax(®) (Anthrax Vaccine Adsorbed), the only vaccine licensed by the U.S. Food and Drug Administration for the protection against anthrax disease. Anthrax is a...

2013-05-30 08:24:04

ANNAPOLIS, Md., May 30, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on a proposed Phase II study of SparVax(®), a next generation recombinant anthrax vaccine. "We are very pleased by the FDA's thorough review of the SparVax(® )stability data and its subsequent...

2013-05-15 08:29:48

PRINCETON, N.J., May 15, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has initiated the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease. The program has...